Colorectal Cancer

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses standards for data interpretation in clinical trials involving ctDNA testing in CRC.

Kanwal P.S. Raghav, MBBS, MD, discusses the mechanism of action of telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

The FDA has approved the Guardant360 CDx as a companion diagnostic for encorafenib in patients with mCRC harboring BRAF V600E mutations.

Rocío García-Carbonero, MD, discusses the rationale of the FRESCO-2 trial of fruquintinib in mCRC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for examining telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Phase 2 data showed atezolizumab plus bevacizumab led to limited responses in patients with metastatic colorectal cancer and an MSI-like gene signature.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

China’s NMPA approved ipilimumab N01 plus sintilimab as neoadjuvant therapy for stage IIB to III resectable MSI-H/dMMR colon cancer.

Signatera MRD positivity predicted improved DFS and OS with adjuvant celecoxib plus chemotherapy vs placebo in resected colorectal cancer.

Nicholas James Hornstein, MD, PhD, discusses the past, present, and future of colorectal cancer management.

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.

Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.

Researchers from UCSF discovered that a combination of immunotherapies can reprogram the immune environment of colon cancer tumors in the liver.